Multicompartment analysis of gadolinium chelate kinetics: Blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging

Journal of Magnetic Resonance Imaging

Volumn 10, Issue 3, 1999, Pages 233-241

  Port, Ruediger E ^a   Knopp, Michael V ^a   Hoffmann, Ulf ^a   Milker Zabel, Stefanie ^a   Brix, Gunnar ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Breast cancer; Dynamic MRI; Gd DTPA; NONMEM; Tissue pharmacokinetics

Indexed keywords

GADOLINIUM CHELATE; GADOLINIUM PENTETATE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTERIAL BLOOD; ARTICLE; BREAST CARCINOMA; BREAST DISEASE; BREAST FIBROADENOMA; BREAST TUMOR; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTRAST ENHANCEMENT; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIGNAL NOISE RATIO;

ADENOCARCINOMA; ADULT; AGED; BAYES THEOREM; BREAST NEOPLASMS; CONTRAST MEDIA; FEMALE; FIBROADENOMA; FIBROCYSTIC BREAST DISEASE; GADOLINIUM DTPA; HUMANS; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED;

EID: 0032845185     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-2586(199909)10:3<233::AID-JMRI3>3.0.CO;2-M     Document Type: Article

References (49)

1. Piccoli CW. Contrast-enhanced breast MRI: factors affecting sensitivity and specificity. Eur Radiol 1997;7(suppl 5):S281-S288.
2. Gilles R, Guinebretiere J-M, Lucidarme O, et al. Nonpalpable breast tumors: diagnosis with contrast-enhanced subtraction MR imagj ing. Radiology 1994;191:625-631.
3. Boetes C, Barentsz JO, Mus RD, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced Turbo-FLASH subtraction technique. Radiology 1994;193:777-781.
4. Fritz-Hansen T, Rostrup E, Larsson HBW, et al. Measurement of the arterial concentration of Gd-DTPA using MRI: a step toward quantitave perfusion imaging. Magn Reson Med 1996;36:225-231.
5. Knopp MV, Brix G, Junkermann HJ, Sinn HP. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. MRI Clin North America 1994;2:633-658.
6. Hoffmann U, Brix G, Knopp MV, Hess T. Lorenz WJ. Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med 1995;33:506-514.
7. Tofts PS, Berkowitz B, Schnall MD. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 1995;33:564-568.
8. Hulka CA, Smith BL, Sgroi DC, et al. Benign and malignant breast lesions: differentiation with echo-planar MR imaging. Radiology 1995;197:33-38.
9. Hulka CA, Edmister WB, Smith BL, et al. Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 1997;205:837-842.
10. Weinmann H-J, Laniado M, Muetzel W. Pharmacokinetics of Gd-DTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys 1984;16:167-172.
11. Larsson HB, Stubgaard M, Frederiksen JL, et al. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med 1990;16:117-131.
12. Furman-Haran E, Margalit R, Grobgeld D, Degani H. Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors. Proc Natl Acad Sci USA 1996;93:6247-6251.
13. Furman-Haran E, Grobgeld D, Degani H. Dynamic contrast-enhanced imaging and analysis at high spatial resolution of MCF7 human breast tumors. J Magn Reson 1997;128:161-171.
14. Tolfts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991;17:357-367.
15. Brix G, Semmler W, Port R, et al. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comp Assist Tomogr 1991;15:612-628.
16. Gowland P, Mansfield P, Bullock P, et al. Dynamic studies of gadolinium uptake in brain tumors using inversion-recovery echoplanar imaging. Magn Reson Med 1992;26:241-258.
17. Mueller-Schimpfle M, Brix G, Layer G, et al. Recurrent rectal cancer: diagnosis with dynamic MR imaging. Radiology 1993;189: 881-889.
18. Hawighorst H. Knapstein PG, Weikel W. et al. Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 1997;57: 4777-4786.
19. Larsson HB, Stubgaard M, Sondergaard L, Henriksen O. In-vivo quantification of the unidirectional influx constant for Gd-diffusion across myocardial capillaries with MR imaging. J Magn Reson Imaging 1994;4:433-440.
20. Larsson HBW, Fritz-Hansen T, Rostrup E, et al. Myocardial perfusion modeling using MRI. Magn Reson Med 1996;35:716-726.
21. Fritz-Hansen T, Rostrup E, Soendergaard L, et al. Capillary transfer constant of Gd-DTPA in the myocardium at rest and during vasodilation assessed by MRI. Magn Reson Med 1998;40:922-929.
22. Krueck WG, Schmiedl UP, Maravilla KR, et al. MR assessment of radiation-induced blood-brain barrier permeability changes in a rat glioma model. AJNR 1994;15:625-632.
23. Tofts PS. Modelling tracer kinetics in dynamic Gd-DTPA imaging. J Magn Reson Imaging 1997;7:91-101.
24. Sheiner LB, Grasela T. An introduction to mixed effect modeling: concepts, definitions, and justification. J Pharmacokin Biopharm 1991;19:11S-24S.
25. Shelner LB, Ludden TM. Population pharmacoklnetics/dynamics. Annu Rev Pharmacol Toxicol 1992;32:185-209.
26. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications, 3rd ed. Baltimore: Williams & Wilkins; 1995. p 158-161.
27. Donahue KM, Weisskoff RM, Burstein D. Water diffusion and exchange as they influence contrast enhancement. J Magn Reson Imag 1997;7:102-110.
28. Port RE, Schlemmer H-P, Bachert P. Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach. Eur J Clin Pharmacol 1994;47:187-193.
29. Port RE, Bachert P, Semmler W. Kinetic modeling of in vivo-nuclear magnetic resonance spectroscopy data: 5-fluorouracil in liver and liver tumors. Clin Pharmacol Ther 1991;49:497-505.
30. Seal SL, Sheiner LB, editors. NONMEM user's guides, NONMEM Project Group. San Francisco: University of San Francisco; 1992.
31. Sheiner LB, Rosenberg B, Marathe W. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokin Biopharm 1977;5:445-479.
32. S-Plus (version 3.1). Seattle, WA: Statistical Sciences; 1992.
33. Koenig SH, Spiller M, Brown III RD, Wolf GL. Relaxation of water protons in the intra-and extracellular regions of blood containing Gd(DTPA). Magn Reson Med 1986;3:791-795.
34. Wilson CBJH, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 1992;52:1592-1597.
35. Weinmann H-J, Brasch RC, Press W-R, Wesbey GE. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Radiol 1984;142:619-624.
36. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-3051.
37. Brix G, Bahner ML, Hoffmann U, Horvath A, Schreiber W. Regional blood flow, capillary permeability, and compartmental volumes: measurement with dynamic CT - initial experience. Radiology 1999; 210:269-276.
38. Eskey CJ, Wolmark N, McDowell CL, Domach MM, Jain RK. Residence time distributions of various tracers in tumors: implications for drug delivery and blood flow measurement. J Natl Cancer Inst 1994;86:293-299.
39. Andrasko J. Water diffusion permeability of human erythrocytes studied by a pulsed gradient NMR technique. Biochim Biophy s Acta 1976;428:304-311.
40. Donahue KM, Burstein D, Manning WJ, Gray ML. Studies of Gd-DTPA relaxivity and proton exchange in tissue. Magn Reson Med 1994;32:66-76.
41. Degani H, Gusis V, Weinstein D, Fields S, Strano S. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nature Med 1997;3:780-782.
42. Williams WM, Huang KC, Chen TS, Warren BS. Dose-dependent elimination of 5-fluoro-2′-deoxyuridine in the monkey (42487). Proc Soc Exp Biol Med 1987;184:326-336.
43. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications, 3rd ed. Baltimore: Williams & Wilkins; 1995. p 318.
44. Benet LZ. General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J PharmSci 1972;61:536-541.
45. Nakashima E, Benet LZ. An integrated approach to pharmacokinetic analysis for linear mammillary systems in which input and exit may occur in/from any compartment. J Pharmacokin Biopharm 1989;17:673-686.
46. Sheiner LB, Grasela T. An introduction to mixed effect modeling: concepts, definitions, and justification. J Pharmacokin Biopharm 1991;19:11S-24S.
47. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 1992;32:185-209.
48. Port RE, Ding RW, Fies T, Schaerer K. Predicting the time course of haemoglobin in children treated with erythropoietin for renal anaemia. Br J Clin Pharmacol 1998;46:461-466.
49. Sheiner LB, Rosenberg B, Marathe W. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokin Biopharm 1977;5:445-479.